Tags

Type your tag names separated by a space and hit enter

Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
J Clin Pharm Ther 2015; 40(6):661-71JC

Abstract

WHAT IS KNOWN AND OBJECTIVE

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as erlotinib or gefitinib are indicated for the treatment of non-small cell lung cancer (NSCLC). EGFR tyrosine kinase domain mutations have been reported to be associated with EGFR-TKI response in patients with NSCLC. Certain patient subgroups in which EGFR somatic mutations are more frequently observed are thought to derive more clinical benefit from EGFR-TKI therapy. We performed a systematic review and meta-analysis to summarize the evidence regarding the association of smoking status with overall survival (OS) and progression-free survival (PFS) in patients with NSCLC receiving EGFR-TKI therapy with erlotinib or gefitinib.

METHODS

Eligible studies were selected by two independent reviewers using the inclusion and exclusion criteria predefined in the protocol. Eligible studies included those evaluating the association of smoking status with OS and PFS in patients with NSCLC receiving erlotinib or gefitinib. Non-clinical studies, case reports, non-peer-reviewed abstracts and non-relevant studies were excluded.

RESULTS AND DISCUSSION

Data on OS and PFS in patients with NSCLC treated with EGFR-TKIs were available in nine and ten trials, respectively. The OS and PFS from both the treatment and control groups were not significantly different between never smokers and former or current smokers (OS: odds ratio [OR], 0·80; 95% confidence interval [CI], 0·63-1·09; PFS: OR, 0·75; 95% CI, 0·49-1·14), respectively. However, in comparison within each smoking group, EGFR-TKI treatment led to more favourable OS and PFS in never smokers (OS: OR, 0·55; 95% CI, 0·42-0·73; PFS: OR, 0·43; 95% CI, 0·33-0·54), compared with former or current smokers (OS: OR, 0·89; 95% CI, 0·80-0·97; PFS: OR, 0·73; 95% CI, 0·62-0·85).

WHAT IS NEW AND CONCLUSION

Among patients with NSCLC receiving EGFR-TKI therapy with erlotinib or gefitinib, never smokers appear to show longer OS and PFS as compared to former or current smokers. However, this is based on indirect comparisons and more robust larger head-to-head trials are required for more robust inferences.

Authors+Show Affiliations

Graduate School of Clinical Pharmacy, CHA University, Gyeonggi-do, Korea.College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu, Korea.College of Pharmacy, Ajou University, Suwon, Korea.College of Medicine, The Catholic University of Korea, Seoul, Korea.College of Pharmacy, Sookmyung Women's University, Seoul, Korea.

Pub Type(s)

Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review

Language

eng

PubMed ID

26573867

Citation

Sohn, H S., et al. "Effect of Smoking Status On Progression-free and Overall Survival in Non-small Cell Lung Cancer Patients Receiving Erlotinib or Gefitinib: a Meta-analysis." Journal of Clinical Pharmacy and Therapeutics, vol. 40, no. 6, 2015, pp. 661-71.
Sohn HS, Kwon JW, Shin S, et al. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis. J Clin Pharm Ther. 2015;40(6):661-71.
Sohn, H. S., Kwon, J. W., Shin, S., Kim, H. S., & Kim, H. (2015). Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis. Journal of Clinical Pharmacy and Therapeutics, 40(6), pp. 661-71. doi:10.1111/jcpt.12332.
Sohn HS, et al. Effect of Smoking Status On Progression-free and Overall Survival in Non-small Cell Lung Cancer Patients Receiving Erlotinib or Gefitinib: a Meta-analysis. J Clin Pharm Ther. 2015;40(6):661-71. PubMed PMID: 26573867.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis. AU - Sohn,H S, AU - Kwon,J-W, AU - Shin,S, AU - Kim,H-S, AU - Kim,H, Y1 - 2015/11/17/ PY - 2015/01/13/received PY - 2015/10/08/accepted PY - 2015/11/18/entrez PY - 2015/11/18/pubmed PY - 2016/10/13/medline KW - erlotinib KW - gefitinib KW - non-small cell lung cancer KW - smoking SP - 661 EP - 71 JF - Journal of clinical pharmacy and therapeutics JO - J Clin Pharm Ther VL - 40 IS - 6 N2 - WHAT IS KNOWN AND OBJECTIVE: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as erlotinib or gefitinib are indicated for the treatment of non-small cell lung cancer (NSCLC). EGFR tyrosine kinase domain mutations have been reported to be associated with EGFR-TKI response in patients with NSCLC. Certain patient subgroups in which EGFR somatic mutations are more frequently observed are thought to derive more clinical benefit from EGFR-TKI therapy. We performed a systematic review and meta-analysis to summarize the evidence regarding the association of smoking status with overall survival (OS) and progression-free survival (PFS) in patients with NSCLC receiving EGFR-TKI therapy with erlotinib or gefitinib. METHODS: Eligible studies were selected by two independent reviewers using the inclusion and exclusion criteria predefined in the protocol. Eligible studies included those evaluating the association of smoking status with OS and PFS in patients with NSCLC receiving erlotinib or gefitinib. Non-clinical studies, case reports, non-peer-reviewed abstracts and non-relevant studies were excluded. RESULTS AND DISCUSSION: Data on OS and PFS in patients with NSCLC treated with EGFR-TKIs were available in nine and ten trials, respectively. The OS and PFS from both the treatment and control groups were not significantly different between never smokers and former or current smokers (OS: odds ratio [OR], 0·80; 95% confidence interval [CI], 0·63-1·09; PFS: OR, 0·75; 95% CI, 0·49-1·14), respectively. However, in comparison within each smoking group, EGFR-TKI treatment led to more favourable OS and PFS in never smokers (OS: OR, 0·55; 95% CI, 0·42-0·73; PFS: OR, 0·43; 95% CI, 0·33-0·54), compared with former or current smokers (OS: OR, 0·89; 95% CI, 0·80-0·97; PFS: OR, 0·73; 95% CI, 0·62-0·85). WHAT IS NEW AND CONCLUSION: Among patients with NSCLC receiving EGFR-TKI therapy with erlotinib or gefitinib, never smokers appear to show longer OS and PFS as compared to former or current smokers. However, this is based on indirect comparisons and more robust larger head-to-head trials are required for more robust inferences. SN - 1365-2710 UR - https://www.unboundmedicine.com/medline/citation/26573867/Effect_of_smoking_status_on_progression_free_and_overall_survival_in_non_small_cell_lung_cancer_patients_receiving_erlotinib_or_gefitinib:_a_meta_analysis_ L2 - https://doi.org/10.1111/jcpt.12332 DB - PRIME DP - Unbound Medicine ER -